Asthma Patents (Class 514/826)
-
Patent number: 7368120Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.Type: GrantFiled: January 31, 2005Date of Patent: May 6, 2008Assignee: Sepracor Inc.Inventors: Gunnar Aberg, John Morley
-
Patent number: 7368104Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.Type: GrantFiled: August 24, 2004Date of Patent: May 6, 2008Assignee: Sosei R&D Ltd.Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
-
Patent number: 7358260Abstract: The invention provides 1-phenethyl-3 (R)-(9[H]-xanthene-9-carbonyloxy)-1 -azoniabicyclo[2.2.2]octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders.Type: GrantFiled: December 8, 2006Date of Patent: April 15, 2008Assignee: Laboratories Almirall, S.A.Inventors: María Dolors Fernandez Forner, María Prat Quiñones, María Antonia Buil Albero
-
Patent number: 7354913Abstract: Inhalable pharmaceutical compositions are provided, for use in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD). These compositions have high storage stability, and include formoterol and a corticosteroid.Type: GrantFiled: February 8, 2005Date of Patent: April 8, 2008Assignee: AstraZeneca ABInventors: Eva Trofast, Karin Malmqvist-Granlund, Per-Gunnar Nilsson, Kyrre Thalberg
-
Patent number: 7273604Abstract: Disclosed is a combination product for use in treating asthma and other respiratory conditions comprising a medicament comprising a surface active phospholipid composition in the form of a fine powder and an antiasthma drug. The product is arranged to be administered to the lungs by inhalation, for example, by the disclosed devices.Type: GrantFiled: October 27, 2004Date of Patent: September 25, 2007Assignee: Britannia Pharmaceuticals LimitedInventors: Brian Andrew Hills, Derek Alan Woodcock, John Nicholas Staniforth
-
Patent number: 7267813Abstract: Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders.Type: GrantFiled: October 5, 2001Date of Patent: September 11, 2007Assignee: Orion CorporationInventors: Wiwik Watanabe, Esko Kauppinen, Petri Ahonen, David Brown, Esa Muttonen
-
Patent number: 7244415Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline anhydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.Type: GrantFiled: March 26, 2003Date of Patent: July 17, 2007Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Christel Schmelzer
-
Patent number: 7229607Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.Type: GrantFiled: October 7, 2002Date of Patent: June 12, 2007Assignee: Sosei R&D LtdInventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
-
Patent number: 7214687Abstract: The invention provides 3 (R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1 -azoniabicyclo[2.2.2]octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, in association with phosphodiesterase 4 inhibitors.Type: GrantFiled: January 3, 2006Date of Patent: May 8, 2007Assignee: Almirall AGInventors: Maria Dolors Fernandez Forner, Maria Prat Quiñones, Maria Antonia Buil Albero
-
Patent number: 7195766Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.Type: GrantFiled: September 10, 2003Date of Patent: March 27, 2007Assignee: National Jewish Medical and Research CenterInventor: Carl W. White
-
Patent number: 7192578Abstract: A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.Type: GrantFiled: August 18, 2003Date of Patent: March 20, 2007Assignee: Genaera CorporationInventors: Roy Clifford Levitt, W. Lee Maloy, U. Prasad Kari, Nicholas C. Nicolaides
-
Patent number: 7172752Abstract: Inhalation particles incorporating, in an individual particle, a combination of a ?hd 2-agonist and a glucocorticosteroid in a predetermined and constant ratio, a process for the preparation thereof and pharmaceutical compositions comprising the inhalation particles. The particles have a narrow particle size distribution and are preferably in the form of spherical crystalline particles with a rough surface. The particles are particularly useful in the treatment of asthma and other respiratory disorders.Type: GrantFiled: October 5, 2001Date of Patent: February 6, 2007Assignee: Orion CorporationInventors: Wiwik Watanabe, Esko Kauppinen, Petri Ahonen, David Brown, Esa Muttonen
-
Patent number: 7107985Abstract: The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as define herein and (b) an adrenergic ?2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.Type: GrantFiled: September 2, 2005Date of Patent: September 19, 2006Assignee: Pfizer, Inc.Inventor: Michael Yeadon
-
Patent number: 7087249Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.Type: GrantFiled: April 23, 2002Date of Patent: August 8, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
-
Patent number: 7074778Abstract: This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and alleviating asthmatic responses to allergen. Exemplary 3-aminosteroid compounds used in the methods of the invention include compounds having the chemical formula (I), wherein X, R1, R2, R3, and R4 groups are as defined herein. The invention also relates to certain novel compounds of formula (I). Moreover, the invention also provides methods for identifying an immunomodulatory 3-aminosteroid compound.Type: GrantFiled: December 11, 2000Date of Patent: July 11, 2006Assignee: Genaera CorporationInventors: Roy C. Levitt, Nicholas C. Nicolaides, William A. Kinney, Steve Jones
-
Patent number: 7045152Abstract: Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.Type: GrantFiled: February 14, 2001Date of Patent: May 16, 2006Assignee: Duke UniversityInventor: Jonathan S. Stamler
-
Patent number: 7029656Abstract: Formulations, methods and devices for producing formulations and methods for nebulizer delivery of formulations of water-insoluble drugs are provided. Also provided are methods for minimizing wastage of drugs administered by nebulizer, and for the achievement of quantitative dosing with diluent from a mass marketed formulations, which because of the mass market is much less costly per dose than formulations manufactured specifically for much lower volume medical use.Type: GrantFiled: December 15, 2000Date of Patent: April 18, 2006Inventor: Robert E. Coifman
-
Patent number: 7011854Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.Type: GrantFiled: February 3, 2003Date of Patent: March 14, 2006Assignee: Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos LdaInventors: Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
-
Patent number: 6994870Abstract: A method and strip for treating allergen-induced airway inflammation. The method includes applying a nasal or skin strip containing a mixture of an allergen and a pharmaceutically acceptable carrier to an individual having allergen-induced airway inflammation in a manner consistent with local nasal immunotherapy.Type: GrantFiled: December 23, 2002Date of Patent: February 7, 2006Inventor: Jaw-Ji Tsai
-
Patent number: 6974803Abstract: The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as defined herein and (b) an adrenergic ?2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.Type: GrantFiled: December 2, 2002Date of Patent: December 13, 2005Assignee: Pfizer IncInventor: Michael Yeadon
-
Patent number: 6964759Abstract: Formulations for the administration through pressurized metered dose aerosol inhalers containing an anticholineric drug in solution in a hydrofluorocarbon propellant, a cosolvent and a low volatility component, and the use thereof in chronic obstructive pulmonary disease.Type: GrantFiled: February 19, 2001Date of Patent: November 15, 2005Assignee: Chiesi Farmaceutici S.p.A.Inventors: David Lewis, David Ganderton, Brian Meakin, Gaetano Brambilla, Alessandra Ferraris
-
Patent number: 6958162Abstract: Pharmaceutical compositions for treating immunological disorders and the preparing method of the same are disclosed, which include alcohol extracts of Radix Dioscorea, Rhizoma Alismatis, Poria cocos (schw) Wolf, and Scutellaria Baicalensis. The compositions are manufactured by novel procedures consisting of decocting using specific concentration ranges of alcohol, filtering, regulating pH value, purifying, concentrating, proportionally mixing, and making a granule powder from lyophilized extract. This invention used both in vitro and in vivo assays to evaluate therapeutic effects of specific combination of herbal plant extracts. The combination of herbal extracts has been able to maximize the anti-inflammatory activity and regulate the secretion of cytokines such as eotaxin and IL-4.Type: GrantFiled: June 30, 2003Date of Patent: October 25, 2005Assignee: Industrial Technology Research InstituteInventors: Rong-Ming Lyu, I-Hong Pan, Jir-mehng Lo, Sue-Fen Jiang, Sheau-Ni Su, Nai-Yun Hsu, Shih Cheng Shen, Hsin-Chieh Wu, Lain-Tze Lee, Yih-Loong Lai, Jaw-Ji Tsai
-
Patent number: 6956030Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: January 22, 2004Date of Patent: October 18, 2005Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6949533Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: November 6, 2003Date of Patent: September 27, 2005Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Patent number: 6897206Abstract: The invention features a method for treating a patient having an inflammatory disorder, by administering to the patient (i) a tricyclic antidepressant (e.g., amoxapine); and (ii) a corticosteroid (e.g., prednisolone) simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit inflammation.Type: GrantFiled: July 9, 2002Date of Patent: May 24, 2005Assignee: CombinatoRx, Inc.Inventors: Robyn Sackeyfio, Jason Fong, Nicole Hurst, Palaniyandi Manivasakam, Edward Roydon Jost-Price, Grant Zimmermann, Curtis Keith, Alexis Borisy
-
Patent number: 6893628Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that the medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when the formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: March 31, 2003Date of Patent: May 17, 2005Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6890517Abstract: A liquid, propellant-free pharmaceutical preparation comprising: (a) a first active substance comprising a tiotropium salt, in a concentration based on tiotropium of between 0.0005% and 5% by weight; (b) a second active substance selected from the group consisting of: an antiallergic, antihistamine, steroid, and leukotriene antagonist; (c) a solvent selected from water or a water/ethanol mixture; and (d) a pharmacologically acceptable preservative, wherein the pH of the preparation is adjusted to between 2.0 and 4.5 with an acid and the tiotropium salt is dissolved in the solvent, optionally including a pharmacologically acceptable complexing agent, stabilizer, a pharmacologically acceptable cosolvent, or other pharmacologically acceptable adjuvants and additives; a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler, and a method of treating asthma or COPD in a patient using the pharmaceutical preparation.Type: GrantFiled: March 24, 2003Date of Patent: May 10, 2005Assignee: Boehringer Ingelheim Pharma KGInventors: Karin Drechsel, Barbara Niklaus-Humke, Christel Schmelzer, Petra Barth
-
Patent number: 6887459Abstract: The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of from 400 ?g to 5000 ?g per ?g of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.Type: GrantFiled: November 28, 2000Date of Patent: May 3, 2005Assignee: Novartis, AGInventor: Barbara Haeberlin
-
Patent number: 6869942Abstract: Inhalable pharmaceutical compositions are provided, for use in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD). These compositions have high storage stability, and include formoterol and a corticosteroid.Type: GrantFiled: May 17, 2001Date of Patent: March 22, 2005Assignee: AstraZeneca ABInventors: Eva Trofast, Karin Malmqvist-Granlund, Per-Gunnar Nilsson, Kyrre Thalberg
-
Patent number: 6866839Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.Type: GrantFiled: June 9, 2003Date of Patent: March 15, 2005Assignee: Sepracor Inc.Inventors: Gunnar Aberg, John Morley
-
Patent number: 6855350Abstract: The present invention relates to the preparation of therapeutic compositions comprising of fermented soy extracts made with lactic acid bacteria and the optional addition of at least a yeast. The invention also relates to therapeutic uses of such extracts in promoting general health, improving the health of subjects, preventing and/or treating cancer, preventing infections, reducing the incidence of infections, treating infections, treating asthma, treating inflammation, modulating the immune system and treating immune disorders.Type: GrantFiled: July 11, 2002Date of Patent: February 15, 2005Assignee: Microbio Co., Ltd.Inventor: Kung-Ming Lu
-
Patent number: 6846841Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Type: GrantFiled: March 28, 2002Date of Patent: January 25, 2005Assignee: Angiotech Pharmaceuticals, Inc.Inventors: William L. Hunter, Lindsay S. Machan, A. Larry Arsenault
-
Patent number: 6844012Abstract: The invention concerns the use of at least a molecule containing selenium, in an amount corresponding to a daily dose of about 2 to 40 mg, even 80 mg of atomic selenium equivalent, on its own or combined with other synergetic molecules for controlling oxidative stress and excessive inflammatory reaction: zinc, vitamin E, vitamin C, iron binder, glutathione precursor, copper and/or copper input binder, for preparing a medicine for treating severe systemic inflammatory response syndrome, in particular any acute infectious condition endangering the patient's life whether of bacterial, parasitic, fungal or viral origin, and any condition corresponding to a severe onset of inflammatory pathology bringing about an exacerbation of cytokine secretion. The invention is applicable in human and veterinary medicine.Type: GrantFiled: August 30, 1999Date of Patent: January 18, 2005Inventors: Xavier Forceville, Dominique Vitoux
-
Patent number: 6833389Abstract: Use of thiamphenicol and derivatives thereof for the preparation of pharmaceutical compositions useful for the treatment Chlamydia pneumoniae infections is described.Type: GrantFiled: December 11, 2001Date of Patent: December 21, 2004Assignee: Zambon Group S.p.A.Inventors: Giovanni Battista Colombo, Domenico Ungheri, Luciano Licciardello, Maria Rita Gismondo, Lorenzo Drago
-
Patent number: 6830764Abstract: Application of an alkaline earth metal salt selected from calcium and strontium salts can steadily denature the allergens those exist in the environment without any coloring trouble on the treated material.Type: GrantFiled: March 12, 2001Date of Patent: December 14, 2004Assignees: Shinto Fine Co., Ltd., Sumitomo Chemical Co., Ltd.Inventors: Keiichiro Inui, Mariko Mikame
-
Patent number: 6824761Abstract: Disclosed is a combination product for use in treating asthma and other respiratory conditions comprising a medicament comprising a surface active phospholipid composition in the form of a fine powder and an antiasthma drug. The product is arranged to be administered to the lungs by inhalation, for example, by the disclosed devices.Type: GrantFiled: September 17, 2001Date of Patent: November 30, 2004Assignee: Britannia Pharmaceuticals LimitedInventors: Brian Andrew Hills, Derek Alan Woodcock, John Nicholas Staniforth
-
Patent number: 6811796Abstract: A method for prevention or therapy of pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria by administration of two kinds of crude drugs—seeds of Cucurbita moschata and flowers of Carthamus tinctorius—and at least one crude drug selected from Plantago asiatica, Lonicera japonica, Glycyrrhiza uralensis, Coix lachrymal-jobi var. ma-yuen, Zingiber officinale, Curcuma longa, Curcuma zedoaria and Artemisia argyi to a patient; and a health food for prevention, or improvement, or reduction of these symptoms containing the above substances.Type: GrantFiled: April 22, 2002Date of Patent: November 2, 2004Assignee: Matsuura Yakugyo Co., Ltd.Inventor: Satoshi Yoshida
-
Patent number: 6790849Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.Type: GrantFiled: March 26, 2002Date of Patent: September 14, 2004Assignee: Sepracor Inc.Inventor: Paul D. Rubin
-
Patent number: 6787532Abstract: There is provided according to the invention a pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament and (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid.Type: GrantFiled: February 4, 2002Date of Patent: September 7, 2004Assignee: SmithKline Beecham CorporationInventors: Keith Biggadike, Amyn P. Sayani, Ian Buxton, Kenton Reed
-
Patent number: 6770635Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: December 4, 1997Date of Patent: August 3, 2004Assignee: Pharos PharmaceuticalsInventor: Clairmont G. Drube
-
Patent number: 6770619Abstract: Lung surfactant compositions are provided which can form a swelling phase when dispersed in a medium containing electrolytes. Hereby, a more active spreading of the lung surfactant into the alveoli can be obtained after administration to the lungs. Further provided are a pharmaceutical composition and a pharmaceutical kit comprising a lung surfactant composition as well as to a method for the treatment, prevention and/or diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with a deficiency of a lung surfactant.Type: GrantFiled: August 31, 2001Date of Patent: August 3, 2004Inventors: Marcus Larsson, Kåre Larsson, Per Wollmer, Burkhard Lachmann, Johannes Jacobus Haitsma
-
Patent number: 6767901Abstract: The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.Type: GrantFiled: July 15, 2002Date of Patent: July 27, 2004Assignee: Altana Pharma AGInventors: Atsuhiro Nagano, Yoshihisa Nishibe, Kazuya Takanashi
-
Patent number: 6759049Abstract: The invention concerns the field of pharmaceutics and dietetics. More particularly, the invention concerns pharmaceutical and/or dietetic mushroom-based compositions, characterised in that they contain one or several edible mushrooms with therapeutic properties and chitosan.Type: GrantFiled: February 25, 2001Date of Patent: July 6, 2004Assignee: Medecine Information Formation S.A.Inventor: Bruno Donatini
-
Patent number: 6756369Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.Type: GrantFiled: March 19, 2002Date of Patent: June 29, 2004Assignee: Vanderbilt UniversityInventors: William M. Mitchell, Charles W. Stratton
-
Patent number: 6753021Abstract: The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of crude extract, its fractions and purified compounds and use of the chloroform fraction of the crude extract as anti-spasmodic, anti-arrhythmic and anti-cholinergic agent.Type: GrantFiled: June 27, 2002Date of Patent: June 22, 2004Assignee: Council of Scientific & Industrial ResearchInventors: Usha Goswami, Nazarine Fernandes
-
Patent number: 6743429Abstract: The present invention relates to the use of calcitonin gene-related peptide (CGRP) in the prevention and alleviation of asthmatic symptoms. In contrast to other therapeutic agents now in use, CGRP combines both bronchoprotector and anti-inflammatory properties. Furthermore, it prevents both early and late phase bronchial responses associated with an asthma attack and its effective dose is small enough that undesirable haemodynamic side effects are not present.Type: GrantFiled: December 30, 1999Date of Patent: June 1, 2004Assignee: Sherbrooke UniversityInventor: Alain Cadieux
-
Patent number: 6737044Abstract: An aerosol composition comprising a propellant and a first particulate material comprising particle having a median aerodynamic diameter within the range 0.05 to 11 &mgr;m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 &mgr;m. The presence of the second particulate material provides good suspension properties, particularly where the propellant is a hydrofluoro alkane.Type: GrantFiled: January 30, 2001Date of Patent: May 18, 2004Assignees: University College Cardiff Consultants Limited, Cardiff Scintigraphics LimitedInventors: Paul Alfred Dickinson, Simon John Warren
-
Patent number: 6723713Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: April 30, 2003Date of Patent: April 20, 2004Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6713509Abstract: This invention relates to a controlled or sustained release formulation designed to deliver a PDE4 inhibitor for treating an inflammatory disease such as asthma or COPD and the like.Type: GrantFiled: August 22, 2001Date of Patent: March 30, 2004Assignee: SmithKline Beecham CorporationInventors: Patrick G. Faulkner, Jaime J. Lucca, Thomas J. Wrzosek
-
Patent number: RE40045Abstract: Pharmaceutical compositions comprising effective amounts of salmeterol (and a physiologically acceptable salt thereof) and fluctuations propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.Type: GrantFiled: September 3, 2004Date of Patent: February 5, 2008Assignee: Glaxo Group LimitedInventor: James B. D. Palmer